September 30, 2016

GlaxoSmithKline plc

Foreign Corrupt Practices Act

SANCTION AMOUNT: $20,000,000

Defendants: GlaxoSmithKline plc

Settlement of allegations that Respondent violated the internal controls and books-and-records provisions of the FCPA based on pay-to-prescribe schemes engaged in by its China-based subsidiaries to increase sales. The SEC found that the schemes spanned a period of years and involved the transfer of money, gifts, and other things of value to governement-affiliated health care professionals, which led to millions of dollars in increased sales for Respondent.

Thank you for submitting some email to us.